ليتوانيا - اللتوانية - SMCA (Valstybinė vaistų kontrolės tarnyba)

mcneil products limited, c/o johnson &johnson limited - cetirizino dihidrochloridas - minkštosios kapsulės - 10 mg - cetirizine

ليتوانيا - اللتوانية - SMCA (Valstybinė vaistų kontrolės tarnyba)

mcneil products limited, c/o johnson &johnson limited - gvajfenezinas - sirupas - 20 mg/ml - guaifenesin

الاتحاد الأوروبي - اللتوانية - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - dantų atmetimas - imunosupresantai - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

ليتوانيا - اللتوانية - SMCA (Valstybinė vaistų kontrolės tarnyba)

procter & gamble services nv/sa, temselaan 100, b-1853 strombeek-bever, belgija. - ketvirtiniai amonio junginiai, alkil-c12-c18-dimetilbenzilamonio chloridai, benzil-c12-c18- alkildimetilo chloridai; ketvirtiniai amonio junginiai, alkil-c12-c18-dimetilbenzilamonio chloridai, benzil-c12-c18- alkildimetilo chloridai - veikliosios medžiagos cas nr.: 68391-01-5, eb nr.: 269-919-4, veikliosios medžiagos pavadinimas: ketvirtiniai amonio junginiai, alkil-c12-c18-dimetilbenzilamonio chloridai, benzil-c12-c18- alkildimetilo chloridai, koncentracija: 0.05% , veiklioji; veikliosios medžiagos cas nr.: 68391-01-5, eb nr.: 269-919-4, veikliosios medžiagos pavadinimas: ketvirtiniai amonio junginiai, alkil-c12-c18-dimetilbenzilamonio chloridai, benzil-c12-c18- alkildimetilo chloridai, koncentracija: 0.05% , veiklioji - dezinfekantai ir algicidai, kurie nėra skirti tiesioginiam žmonių ar gyvūnų naudojimui

الاتحاد الأوروبي - اللتوانية - EMA (European Medicines Agency)

ptc therapeutics international limited - eladocagene exuparvovec - amino rūgšties metabolizmas, įgimtos klaidos - enzymes, other alimentary tract and metabolism products - upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic l amino acid decarboxylase (aadc) deficiency with a severe phenotype (see section 5.

ليتوانيا - اللتوانية - SMCA (Valstybinė vaistų kontrolės tarnyba)

zentiva k.s. - salmeterolis/flutikazono propionatas - dozuoti įkvepiamieji milteliai - 50 µg/100 µg/dozėje - salmeterol and fluticasone

ليتوانيا - اللتوانية - SMCA (Valstybinė vaistų kontrolės tarnyba)

zentiva k.s. - salmeterolis/flutikazono propionatas - dozuoti įkvepiamieji milteliai - 50 µg/250 µg/dozėje - salmeterol and fluticasone

ليتوانيا - اللتوانية - SMCA (Valstybinė vaistų kontrolės tarnyba)

zentiva k.s. - salmeterolis/flutikazono propionatas - dozuoti įkvepiamieji milteliai - 50 µg/500 µg/dozėje - salmeterol and fluticasone

ليتوانيا - اللتوانية - SMCA (Valstybinė vaistų kontrolės tarnyba)

norbrook laboratories (ireland) limited (airija) - intramaminė suspensija - vienkartiniame švirkšte yra: cloxacillin (as benzathine salt) - 500 mg; excipients up to 4.5 g - karvėms, sergančioms mastitu, gydyti tuojau po paskutinio melžimo ir infekcijų profilaktikai užtrūkimo metu.

الاتحاد الأوروبي - اللتوانية - EMA (European Medicines Agency)

viatris limited - klopidogrelio besilatas - peripheral vascular diseases; stroke; myocardial infarction - antitromboziniai vaistai - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st segmento pakilimu ūmus miokardo infarktas, kartu su asr medikamentais gydytų pacientų, atitinkančių trombolizinė terapija. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. daugiau informacijos, skaitykite skyrių 5.